Asset Dedication’s Phaxiam Therapeutics PHXM Stock Holding History
Bought
Maintained
Sold
Asset Dedication's PHXM Position: Q2 2024 in Review
Asset Dedication sold out of Phaxiam Therapeutics (PHXM) in Q2 2024, closing a stake of 400 shares — an estimated $1K sold.
Asset Dedication first reported a position in PHXM in Q3 2022 and held it in 7 quarters. The position peaked at $4K in Q1 2023. 0 funds tracked by Wall St. Rank hold PHXM as of Q2 2024.
- Asset Dedication reported no remaining Phaxiam Therapeutics position as of Q2 2024 after selling out during the quarter.
- Asset Dedication sold 400 Phaxiam Therapeutics shares in Q2 2024, an estimated $1K.
- Asset Dedication first reported a position in Phaxiam Therapeutics in Q3 2022 and held it in 7 quarters.
- Asset Dedication's Phaxiam Therapeutics position peaked at $4K in Q1 2023.
- 0 funds tracked by Wall St. Rank held Phaxiam Therapeutics as of Q2 2024.
Based on Asset Dedication's 13F filing for Q2 2024, filed 6 Aug 2024.